Trial · NCT02019667
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline on the Adaptive Behavior Assessment System (ABAS) Test at the End of the Study Drug and Placebo Treatment Periods | Placebo | 5.2 | Standard Deviation 7.1 | scores on a scale | |
| Change From Baseline on the Adaptive Behavior Assessment System (ABAS) Test at the End of the Study Drug and Placebo Treatment Periods | Study Drug | 4.5 | Standard Deviation 7.5 | scores on a scale | |
| Change From Baseline of TMS Measurement of Motor Threshold at the End of the Study Drug and Placebo Treatment Periods | Placebo | -2 | Standard Deviation 7.1 | percentage of stimulator output | |
| Change From Baseline of TMS Measurement of Motor Threshold at the End of the Study Drug and Placebo Treatment Periods | Study Drug | -0.5 | Standard Deviation 6.8 | percentage of stimulator output | |
| Change From Baseline of TMS Measurement of Intracortical Facilitation at the End of the Study Drug and Placebo Treatment Periods | Placebo | 49.9 | Standard Deviation 61.9 | ratio of MEP amplitude | |
| Change From Baseline of TMS Measurement of Intracortical Facilitation at the End of the Study Drug and Placebo Treatment Periods | Study Drug | 40.5 | Standard Deviation 50.2 | ratio of MEP amplitude | |
| Change From Baseline of TMS Measurement of Short Interval Intracortical Inhibition (Short ICI) at the End of the Study Drug and Placebo Treatment Periods | Placebo | 35.5 | Standard Deviation 123.4 | ratio of MEP amplitude | |
| Change From Baseline of TMS Measurement of Short Interval Intracortical Inhibition (Short ICI) at the End of the Study Drug and Placebo Treatment Periods | Study Drug | -11.0 | Standard Deviation 54.8 | ratio of MEP amplitude | |
| Change From Baseline of TMS Measurement of Long Interval Intracortical Inhibition (Long ICI) at the End of the Study Drug and Placebo Treatment Periods | Placebo | -9.3 | Standard Deviation 112.0 | ratio of MEP amplitude | |
| Change From Baseline of TMS Measurement of Long Interval Intracortical Inhibition (Long ICI) at the End of the Study Drug and Placebo Treatment Periods | Study Drug | 0.3 | Standard Deviation 98.6 | ratio of MEP amplitude | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Placebo | 0 | 0 | Participants | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Study Drug | 0 | 0 | Participants | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Placebo | 1 | 14 | Participants | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Study Drug | 1 | 15 | Participants | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Placebo | 2 | 4 | Participants | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Study Drug | 2 | 3 | Participants | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Placebo | 3 | 0 | Participants | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Study Drug | 3 | 0 | Participants | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Placebo | 4 | 0 | Participants | |
| Results of Physical Examination at the End of the Study Drug and Placebo Treatment Periods | Study Drug | 4 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02019667/results